Modern Lipidology in CVD Prevention: The Rise of Lipoprotein(a)
EMJ Podcast: Insights For Healthcare Professionals
Release Date: 10/01/2026
EMJ Podcast: Insights For Healthcare Professionals
This podcast was developed and funded by LEO Pharma and is intended only for healthcare professionals. Please note that this podcast was developed in accordance with the betamethasone dipropionate, calcipotriol monohydrate SmPCs. Click for the UK Enstilar (betamethasone diproprionate, calcipotriol monohydrate) SmPC. Enstilar is indicated for the topical treatment of psoriasis vulgaris in adults. Please be aware that the label within your country may differ due to local regulations, and you should always consult your own label for prescribing and safety information about Enstilar. Topics...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
How can clinical trials better answer the questions that matter to patients and clinicians? In the final episode, Nuru Noor explains the importance of the estimand framework, how to interpret apparently conflicting trial results, and what Bayesian re-analysis can add to the evidence. The discussion also considers how future trials could compare treatment strategies rather than individual drugs, and which developments are most likely to transform inflammatory bowel disease research and care over the next 5–10 years. Timestamps: 00:34 – The estimand framework 01:58 – Conflicting...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
Can biomarkers help clinicians move beyond trial and error in inflammatory bowel disease treatment? In Part 2, Nuru Noor explores why precision medicine has been difficult to translate into routine clinical practice, and how metabolomics, lipidomics, and genotype–phenotype associations could improve our understanding of individual patients. He also discusses the challenges of choosing between an expanding range of therapies and determining when combination treatment offers meaningful benefits. Timestamps: 00:36 – Translating research into clinical practice 03:12 –...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
In this episode of Onc Now, Lennard Lee explores the latest advances in personalised cancer vaccines, emerging clinical evidence, and the potential of agentic AI scientists to accelerate cancer discovery, transform drug development and shape the future of oncology. Timestamps 00:00 - Introduction 00:55 - Origin of interest in cancer vaccines 02:40 - Latest developments in cancer vaccines 04:30 - Who benefits from cancer vaccines? 09:45 - Expanding access to cancer vaccines 13:35 - AI and personalised vaccine development 20:55 -...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
How is the treatment paradigm for inflammatory bowel disease changing? Nuru Noor joins host Saranya Ravindran to discuss the impact of the PROFILE trial on Crohn’s disease management, the role of early treatment, and the importance of long-term outcomes. This episode explores treat-to-target strategies, balancing objective measures of inflammation with patients’ experiences, and deciding when treatment escalation is appropriate. Timestamps: 00:38 - The PROFILE trial 04:15 – Importance of patient quality of life 05:40 – Heterogeneity in IBD 07:34 – Balancing treatment benefit,...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
How much do we really understand about modern inflammatory bowel disease (IBD) care? In this quickfire episode, Nuru Noor answers key questions on personalised medicine, treatment success, emerging research, biomarkers, and the growing range of IBD therapies. Discover his perspectives on what the field still misunderstands and what needs to change to improve outcomes for patients.
info_outlineEMJ Podcast: Insights For Healthcare Professionals
This podcast has been funded by Castle Biosciences. Traditional staging remains the foundation of risk assessment in cutaneous melanoma and cutaneous squamous cell carcinoma (cSCC), but it does not always tell the full story. In T1b–T2a melanoma, the decision on sentinel lymph node biopsy (SLNB) is not always clear, and in cSCC, clinicopathologic risk factors are incomplete predictors of metastatic risk. In this episode, Mohs and dermatologic surgeon Brent Moody joins host Sue Saville to discuss how gene expression profile (GEP) testing may add tumor biology to the staging information...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
In this episode of Hema Now, we sit down with Toby Eyre, Consultant Haematologist at Oxford University Hospitals, UK, to explore the latest advances in lymphoma and chronic lymphocytic leukaemia, discuss unanswered questions in mantle cell lymphoma, and consider how emerging research is shaping the future of lymphoma care. Timestamps 00:00 - Introduction 01:04 - Journey into haematology and lymphoma 04:34 - Working at Oxford University Hospitals 06:55 - Advances in lymphoma and CLL 11:00 - Unanswered questions in mantle cell lymphoma 16:22...
info_outlineEMJ Podcast: Insights For Healthcare Professionals
What will cardiovascular prevention look like 10 years from now? In this forward-looking episode, Kausik Ray discusses emerging technologies and therapies that could transform clinical practice, including AI, digital health tools, genomics, polygenic risk scoring, and RNA-based medicines. Timestamps: 00:00 – 01:09: Intro 01:10 – 03:46: Population interventions 03:47 – 06:43: Data opportunities 06:43 – 08:51: Novel therapies 08:52 – 11:03: Future prevention
info_outlineEMJ Podcast: Insights For Healthcare Professionals
The global rise in obesity, Type 2 diabetes, and chronic kidney disease is driving an increasing burden of cardiovascular disease. Kausik Ray examines the growing intersection between metabolic and cardiovascular health, highlighting the importance of earlier intervention, comprehensive risk assessment, and integrated care. Timestamps: 00:00 – 01:20: Intro 01:21 – 03:40: Cardiometabolic risk 03:41 – 06:20: Lifestyle interventions 06:21 – 10:19: Early intervention
info_outlineWhy has Lipoprotein(a) emerged as one of the hottest topics in preventive cardiology? In Part 2, Professor Devaki Nair explains when clinicians should measure Lipoprotein(a), how elevated levels influence cardiovascular risk, and how emerging targeted therapies could transform prevention strategies in the coming decade.
Timestamps:
00:00 – 00:40: Introduction
00:40 – 03:03: Lipoprotein(a)’s Rise
03:03 – 04:58: Measuring Lipoprotein(a)
04:58 – 08:04: Cardiovascular Risk
08:04 – 10:04: Targeted Therapies
09:28 – 12:12: Patient Referral